Showing 2401-2410 of 5909 results for "".
- Bausch + Lomb Announces Leadership Changeshttps://modernod.com/news/bausch-lomb-announces-leadership-changes/2481644/Bausch + Lomb announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the comp
- Research: Protein Deletion Could Treat Age and Diabetes-Induced Eye Diseaseshttps://modernod.com/news/research-protein-deletion-could-treat-age-and-diabetes-induced-eye-diseases/2481627/Researchers at the Wayne State University School of Medicine in Detroit say they have provided evidence that depletion of a certain protein in the body can treat age and diabetes-induced retinal diseases, according to a university news release. The protein, called vascular cell ad
- Euclid and Visionary Optics Announce Interactive Specialty Lens Forums in Cities Across the UShttps://modernod.com/news/euclid-and-visionary-optics-announce-interactive-specialty-lens-forums-in-cities-across-the-us/2481620/Euclid Vision is joining forces with Visionary Optics to host multiple specialty contact lens dinner discussions in cities around the US. The program,
- Delta Gamma Foundation Awards RestoringVision with Grant to Serve People in Need of Vision Services and Eyeglasses in the UShttps://modernod.com/news/delta-gamma-foundation-awards-restoringvision-with-grant-to-serve-people-in-need-of-vision-services-and-eyeglasses-in-the-us/2481609/RestoringVision, a global nonprofit, recently won its third Service for Sight grant from the Delta Gamma Foundation. The funding will support bringing vision services and eyeglasses to 270,000 low-income people in the United States, according to RestoringVision. The award supports
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Johnson & Johnson Vision to Present and Support 43 Company-Sponsored and Investigator-Led Studies at ASCRShttps://modernod.com/news/johnson-johnson-vision-to-present-and-support-43-company-sponsored-and-investigator-led-studies-at-ascrs/2481593/Johnson & Johnson Vision will present and support 43 company-sponsored and investigator-led studies evaluating innovation, outcomes and satisfaction rates across its surgical portfolio at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, May 5-8
- Precision Eye Therapy for Dogs Ready for Human Clinical Developmenthttps://modernod.com/news/precision-eye-therapy-for-dogs-ready-for-human-clinical-development/2481576/A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with retinitis pigmentosa, according to a university news release. Simon Petersen-Jones, professor and Donald R. Myers and Wil
- EssilorLuxottica Unveils 4-Year Clinical Trial Results of its Essilor Stellest Lens athttps://modernod.com/news/essilorluxottica-unveils-4-year-clinical-trial-results-of-its-essilor-stellest-lens-at-arvo-at/2481572/EssilorLuxottica presented the 4-year clinical trial results of its Essilor Stellest lens for myopia control at the 2023 ARVO annual meeting in New Orleans. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial ey
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau